{"id":"W3211997738","doi":"10.1182/blood-2021-147937","title":"Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); BC Cancer Agency; Jewish General Hospital","funders":"","keywords":"Tolerability; Dosing; Medicine; Pharmacokinetics; Refractory (planetary science); Internal medicine; Neutropenia; Cytokine release syndrome; Gastroenterology; Toxicity; Adverse effect; Pharmacology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003626165,0.0004216631,0.0007424817,0.0002375805,0.0002014011,0.0004463064,0.0003976843,0.0003917845,0.001914825],"category_scores_gemma":[0.0003248639,0.000202993,0.0004268627,0.0002353684,0.0003355374,0.0003266886,0.000169101,0.001418713,0.000409225],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003566519,"about_ca_system_score_gemma":0.0004636887,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004339499,"about_ca_topic_score_gemma":0.001513216,"domain_scores_codex":[0.9998475,0.00004560023,0.0000114343,0.00003309515,0.00002650019,0.00003588732],"domain_scores_gemma":[0.9997868,0.00003740856,0.0000493488,0.00002883161,0.00001096396,0.0000867292],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1986256,0.06919606,0.01739206,0.001071409,0.0009679066,0.0003193837,0.0003822526,0.003271461,0.2539995,0.0002857831,0.003868428,0.4506201],"study_design_scores_gemma":[0.08928229,0.8223935,0.05201309,0.00007449059,0.0005435644,0.000539266,0.00009763108,0.003219986,0.02762526,0.0001952511,0.003977551,0.00003799183],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973336,0.001142639,0.0003152298,0.00005229769,0.0000200221,0.0003022966,0.0001466037,0.00005043339,0.0006369881],"genre_scores_gemma":[0.997995,0.0004693856,0.0005313086,0.0001140158,0.00002200368,0.0002000339,0.0002378882,0.000007568109,0.0004228273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001914825,"threshold_uncertainty_score":0.006405771,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01330003227611755,"score_gpt":0.2837511359260015,"score_spread":0.270451103649884,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}